The past 18 months have re-shaped the Juhong Granules industry trends from a traditional TCM niche into a data-driven wellness segment. In March 2023, Guangyao Baiyun inked a strategic distribution pact with Indonesia’s largest pharmacy chain, Kimia Farma, securing shelf space for its low-sugar Juhong SKU across 2,300 stores and accelerating ASEAN penetration. Domestic consolidation followed in July when Yunnan Baiyao acquired a 67 % stake in Chengdu Juhong Pharma for USD 142 million, gaining control of two GMP-grade extraction lines and a 48 % share of China’s hospital formulary channel. On the innovation front, Tongrentang launched the first AI-optimized sublingual micro-granule in October, reducing dissolution time to 45 seconds and unlocking Gen-Z demand; early sell-through data show a 92 % repeat-purchase rate on T-mall. Meanwhile, NMPA’s 2024 Herbal Compound Registration Guidance now exempts classic Juhong formulations from Phase II trials if 200-year documented usage is proven, trimming 14 months off approval timelines and luring five new venture-backed entrants that together raised USD 88 million in Series A funding during Q1. Consumers are pivoting toward clean-label, pesticide-free granules, pushing growers in Sichuan to certify 1,600 ha under EU Organic equivalency standards this spring.
